# A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster

> **NCT05609045** · PHASE1 · WITHDRAWN · sponsor: **Wuhan Rhegen Biotechnology Co., Ltd.**

## Conditions studied

- COVID-19 Pandemic

## Interventions

- **BIOLOGICAL:** Lyophilized COVID-19 mRNA Vaccine
- **DRUG:** Sodium chloride

## Key facts

- **NCT ID:** NCT05609045
- **Lead sponsor:** Wuhan Rhegen Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2023-08
- **Final completion:** 2023-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** business strategy adjustment
- **Last updated:** 2023-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05609045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05609045, "A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05609045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*